Identification of an IL-1-induced gene expression pattern in AR+ PCa cells that mimics the molecular phenotype of AR PCa cells

Shayna E. Thomas-Jardin, Mohammed S. Kanchwala, Joan Jacob, Sana Merchant, Rachel K. Meade, Nagham M. Gahnim, Afshan F. Nawas, Chao Xing, Nikki A. Delk

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: In immunosurveillance, bone-derived immune cells infiltrate the tumor and secrete inflammatory cytokines to destroy cancer cells. However, cancer cells have evolved mechanisms to usurp inflammatory cytokines to promote tumor progression. In particular, the inflammatory cytokine, interleukin-1 (IL-1), is elevated in prostate cancer (PCa) patient tissue and serum, and promotes PCa bone metastasis. IL-1 also represses androgen receptor (AR) accumulation and activity in PCa cells, yet the cells remain viable and tumorigenic; suggesting that IL-1 may also contribute to AR-targeted therapy resistance. Furthermore, IL-1 and AR protein levels negatively correlate in PCa tumor cells. Taken together, we hypothesize that IL-1 reprograms AR positive (AR+) PCa cells into AR negative (AR) PCa cells that co-opt IL-1 signaling to ensure AR-independent survival and tumor progression in the inflammatory tumor microenvironment. Methods: LNCaP and PC3 PCa cells were treated with IL-1β or HS-5 bone marrow stromal cell (BMSC) conditioned medium and analyzed by RNA sequencing and RT-QPCR. To verify genes identified by RNA sequencing, LNCaP, MDA-PCa-2b, PC3, and DU145 PCa cell lines were treated with the IL-1 family members, IL-1α or IL-1β, or exposed to HS-5 BMSC in the presence or absence of Interleukin-1 Receptor Antagonist (IL-1RA). Treated cells were analyzed by western blot and/or RT-QPCR. Results: Comparative analysis of sequencing data from the AR+ LNCaP PCa cell line versus the AR PC3 PCa cell line reveals an IL-1-conferred gene suite in LNCaP cells that is constitutive in PC3 cells. Bioinformatics analysis of the IL-1 regulated gene suite revealed that inflammatory and immune response pathways are primarily elicited; likely facilitating PCa cell survival and tumorigenicity in an inflammatory tumor microenvironment. Conclusions: Our data supports that IL-1 reprograms AR+ PCa cells to mimic AR PCa gene expression patterns that favor AR-targeted treatment resistance and cell survival.

Original languageEnglish (US)
Pages (from-to)595-606
Number of pages12
JournalProstate
Volume78
Issue number8
DOIs
StatePublished - Jun 1 2018

Fingerprint

Androgen Receptors
Interleukin-1
Prostatic Neoplasms
Phenotype
Gene Expression
RNA Sequence Analysis
Neoplasms
Tumor Microenvironment
Interleukin-1 Receptors
Cytokines
Mesenchymal Stromal Cells
Cell Line
Cell Survival
Genes
Immunologic Monitoring
Bone Neoplasms
Neoplasm Genes
Conditioned Culture Medium
Computational Biology

Keywords

  • androgen receptor
  • gene expression pattern
  • interleukin-1
  • prostate cancer
  • treatment resistance

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Thomas-Jardin, S. E., Kanchwala, M. S., Jacob, J., Merchant, S., Meade, R. K., Gahnim, N. M., ... Delk, N. A. (2018). Identification of an IL-1-induced gene expression pattern in AR+ PCa cells that mimics the molecular phenotype of AR PCa cells. Prostate, 78(8), 595-606. https://doi.org/10.1002/pros.23504

Identification of an IL-1-induced gene expression pattern in AR+ PCa cells that mimics the molecular phenotype of AR PCa cells. / Thomas-Jardin, Shayna E.; Kanchwala, Mohammed S.; Jacob, Joan; Merchant, Sana; Meade, Rachel K.; Gahnim, Nagham M.; Nawas, Afshan F.; Xing, Chao; Delk, Nikki A.

In: Prostate, Vol. 78, No. 8, 01.06.2018, p. 595-606.

Research output: Contribution to journalArticle

Thomas-Jardin, SE, Kanchwala, MS, Jacob, J, Merchant, S, Meade, RK, Gahnim, NM, Nawas, AF, Xing, C & Delk, NA 2018, 'Identification of an IL-1-induced gene expression pattern in AR+ PCa cells that mimics the molecular phenotype of AR PCa cells', Prostate, vol. 78, no. 8, pp. 595-606. https://doi.org/10.1002/pros.23504
Thomas-Jardin, Shayna E. ; Kanchwala, Mohammed S. ; Jacob, Joan ; Merchant, Sana ; Meade, Rachel K. ; Gahnim, Nagham M. ; Nawas, Afshan F. ; Xing, Chao ; Delk, Nikki A. / Identification of an IL-1-induced gene expression pattern in AR+ PCa cells that mimics the molecular phenotype of AR PCa cells. In: Prostate. 2018 ; Vol. 78, No. 8. pp. 595-606.
@article{23ebe7017d9943bf99d9292882d1e283,
title = "Identification of an IL-1-induced gene expression pattern in AR+ PCa cells that mimics the molecular phenotype of AR− PCa cells",
abstract = "Background: In immunosurveillance, bone-derived immune cells infiltrate the tumor and secrete inflammatory cytokines to destroy cancer cells. However, cancer cells have evolved mechanisms to usurp inflammatory cytokines to promote tumor progression. In particular, the inflammatory cytokine, interleukin-1 (IL-1), is elevated in prostate cancer (PCa) patient tissue and serum, and promotes PCa bone metastasis. IL-1 also represses androgen receptor (AR) accumulation and activity in PCa cells, yet the cells remain viable and tumorigenic; suggesting that IL-1 may also contribute to AR-targeted therapy resistance. Furthermore, IL-1 and AR protein levels negatively correlate in PCa tumor cells. Taken together, we hypothesize that IL-1 reprograms AR positive (AR+) PCa cells into AR negative (AR−) PCa cells that co-opt IL-1 signaling to ensure AR-independent survival and tumor progression in the inflammatory tumor microenvironment. Methods: LNCaP and PC3 PCa cells were treated with IL-1β or HS-5 bone marrow stromal cell (BMSC) conditioned medium and analyzed by RNA sequencing and RT-QPCR. To verify genes identified by RNA sequencing, LNCaP, MDA-PCa-2b, PC3, and DU145 PCa cell lines were treated with the IL-1 family members, IL-1α or IL-1β, or exposed to HS-5 BMSC in the presence or absence of Interleukin-1 Receptor Antagonist (IL-1RA). Treated cells were analyzed by western blot and/or RT-QPCR. Results: Comparative analysis of sequencing data from the AR+ LNCaP PCa cell line versus the AR− PC3 PCa cell line reveals an IL-1-conferred gene suite in LNCaP cells that is constitutive in PC3 cells. Bioinformatics analysis of the IL-1 regulated gene suite revealed that inflammatory and immune response pathways are primarily elicited; likely facilitating PCa cell survival and tumorigenicity in an inflammatory tumor microenvironment. Conclusions: Our data supports that IL-1 reprograms AR+ PCa cells to mimic AR− PCa gene expression patterns that favor AR-targeted treatment resistance and cell survival.",
keywords = "androgen receptor, gene expression pattern, interleukin-1, prostate cancer, treatment resistance",
author = "Thomas-Jardin, {Shayna E.} and Kanchwala, {Mohammed S.} and Joan Jacob and Sana Merchant and Meade, {Rachel K.} and Gahnim, {Nagham M.} and Nawas, {Afshan F.} and Chao Xing and Delk, {Nikki A.}",
year = "2018",
month = "6",
day = "1",
doi = "10.1002/pros.23504",
language = "English (US)",
volume = "78",
pages = "595--606",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "8",

}

TY - JOUR

T1 - Identification of an IL-1-induced gene expression pattern in AR+ PCa cells that mimics the molecular phenotype of AR− PCa cells

AU - Thomas-Jardin, Shayna E.

AU - Kanchwala, Mohammed S.

AU - Jacob, Joan

AU - Merchant, Sana

AU - Meade, Rachel K.

AU - Gahnim, Nagham M.

AU - Nawas, Afshan F.

AU - Xing, Chao

AU - Delk, Nikki A.

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Background: In immunosurveillance, bone-derived immune cells infiltrate the tumor and secrete inflammatory cytokines to destroy cancer cells. However, cancer cells have evolved mechanisms to usurp inflammatory cytokines to promote tumor progression. In particular, the inflammatory cytokine, interleukin-1 (IL-1), is elevated in prostate cancer (PCa) patient tissue and serum, and promotes PCa bone metastasis. IL-1 also represses androgen receptor (AR) accumulation and activity in PCa cells, yet the cells remain viable and tumorigenic; suggesting that IL-1 may also contribute to AR-targeted therapy resistance. Furthermore, IL-1 and AR protein levels negatively correlate in PCa tumor cells. Taken together, we hypothesize that IL-1 reprograms AR positive (AR+) PCa cells into AR negative (AR−) PCa cells that co-opt IL-1 signaling to ensure AR-independent survival and tumor progression in the inflammatory tumor microenvironment. Methods: LNCaP and PC3 PCa cells were treated with IL-1β or HS-5 bone marrow stromal cell (BMSC) conditioned medium and analyzed by RNA sequencing and RT-QPCR. To verify genes identified by RNA sequencing, LNCaP, MDA-PCa-2b, PC3, and DU145 PCa cell lines were treated with the IL-1 family members, IL-1α or IL-1β, or exposed to HS-5 BMSC in the presence or absence of Interleukin-1 Receptor Antagonist (IL-1RA). Treated cells were analyzed by western blot and/or RT-QPCR. Results: Comparative analysis of sequencing data from the AR+ LNCaP PCa cell line versus the AR− PC3 PCa cell line reveals an IL-1-conferred gene suite in LNCaP cells that is constitutive in PC3 cells. Bioinformatics analysis of the IL-1 regulated gene suite revealed that inflammatory and immune response pathways are primarily elicited; likely facilitating PCa cell survival and tumorigenicity in an inflammatory tumor microenvironment. Conclusions: Our data supports that IL-1 reprograms AR+ PCa cells to mimic AR− PCa gene expression patterns that favor AR-targeted treatment resistance and cell survival.

AB - Background: In immunosurveillance, bone-derived immune cells infiltrate the tumor and secrete inflammatory cytokines to destroy cancer cells. However, cancer cells have evolved mechanisms to usurp inflammatory cytokines to promote tumor progression. In particular, the inflammatory cytokine, interleukin-1 (IL-1), is elevated in prostate cancer (PCa) patient tissue and serum, and promotes PCa bone metastasis. IL-1 also represses androgen receptor (AR) accumulation and activity in PCa cells, yet the cells remain viable and tumorigenic; suggesting that IL-1 may also contribute to AR-targeted therapy resistance. Furthermore, IL-1 and AR protein levels negatively correlate in PCa tumor cells. Taken together, we hypothesize that IL-1 reprograms AR positive (AR+) PCa cells into AR negative (AR−) PCa cells that co-opt IL-1 signaling to ensure AR-independent survival and tumor progression in the inflammatory tumor microenvironment. Methods: LNCaP and PC3 PCa cells were treated with IL-1β or HS-5 bone marrow stromal cell (BMSC) conditioned medium and analyzed by RNA sequencing and RT-QPCR. To verify genes identified by RNA sequencing, LNCaP, MDA-PCa-2b, PC3, and DU145 PCa cell lines were treated with the IL-1 family members, IL-1α or IL-1β, or exposed to HS-5 BMSC in the presence or absence of Interleukin-1 Receptor Antagonist (IL-1RA). Treated cells were analyzed by western blot and/or RT-QPCR. Results: Comparative analysis of sequencing data from the AR+ LNCaP PCa cell line versus the AR− PC3 PCa cell line reveals an IL-1-conferred gene suite in LNCaP cells that is constitutive in PC3 cells. Bioinformatics analysis of the IL-1 regulated gene suite revealed that inflammatory and immune response pathways are primarily elicited; likely facilitating PCa cell survival and tumorigenicity in an inflammatory tumor microenvironment. Conclusions: Our data supports that IL-1 reprograms AR+ PCa cells to mimic AR− PCa gene expression patterns that favor AR-targeted treatment resistance and cell survival.

KW - androgen receptor

KW - gene expression pattern

KW - interleukin-1

KW - prostate cancer

KW - treatment resistance

UR - http://www.scopus.com/inward/record.url?scp=85045146385&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045146385&partnerID=8YFLogxK

U2 - 10.1002/pros.23504

DO - 10.1002/pros.23504

M3 - Article

C2 - 29527701

AN - SCOPUS:85045146385

VL - 78

SP - 595

EP - 606

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 8

ER -